Interferon α2b gene delivery using adenoviral vector causes inhibition of tumor growth in xenograft models from a variety of cancers-Reference-Cited by-同舟云学术

Interferon α2b gene delivery using adenoviral vector causes inhibition of tumor growth in xenograft models from a variety of cancers

Published:2001-10 Issue:10 Volume:8 Page:788-795
ISSN:0929-1903
Container-title:Cancer Gene Therapy
language:en
Short-container-title:Cancer Gene Ther

Author:

Iqbal Ahmed C M,Johnson Duane E,Demers G William,Engler Heidren,Howe John A,Wills Ken N,Wen Shu-Fen,Shinoda Jeremy,Beltran Josie,Nodelman Margarita,Machemer Todd,Maneval Dan C,Nagabhushan Tatanahalli L,Sugarman Barry J

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Molecular Biology,Molecular Medicine

Link

http://www.nature.com/articles/7700364.pdf

Reference26 articles.

1. Bordens R, Grossberg SE, Trotta PP, et al . Molecular and biologic characterization of interferon α2b Semin Oncol 1987 24: 41–51

2. Gutterman JU . Cytokine therapeutics: lessons from interferon α Proc Natl Acad Sci USA 1994 91: 1198–1205

3. Pfeffer LM, Dinarrello CA, Herberman RB, et al . Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons Cancer Res 1998 58: 2489–2499

4. Einhorn S, Grander D . Why do so many cancer patients fail to respond to interferon therapy J Interferon Cytokine Res 1996 16: 275–281

5. Gutterman JU, Fine S, Quesada J, et al . Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance and biologic effect in cancer patients Ann Intern Med 1982 96: 549–556

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer;Expert Opinion on Biological Therapy;2024-06-02

2. Tyrosine phosphorylation of IRF3 by BLK facilitates its sufficient activation and innate antiviral response;PLOS Pathogens;2023-10-23

3. Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approval;Frontiers in Immunology;2023-08-29

4. Next generation drugs in urothelial cancer: adenoviruses in the treatment of BCG-unresponsive nonmuscle invasive bladder cancer;memo - Magazine of European Medical Oncology;2023-07-25

5. NK Cell-Targeted Immunotherapies in Bladder Cancer: Beyond Checkpoint Inhibitors;Bladder Cancer;2023-06-27